Verapamil

From Wikipedia, the free encyclopedia

(Redirected from Isoptin)
Jump to: navigation, search
Verapamil
Systematic (IUPAC) name
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-
dimethoxyphenyl)ethyl-methyl-amino]
-2-(1-methylethyl)pentanenitrile
Identifiers
CAS number 52-53-9
ATC code C08DA01
PubChem 2520
DrugBank APRD00335
Chemical data
Formula C27H38N2O4 
Mol. mass 454.602 g/mol
Pharmacokinetic data
Bioavailability 35.1%
Metabolism Hepatic
Half life 2.8-7.4 hours
Excretion Renal: 11%
Therapeutic considerations
Pregnancy cat.

C(US)

Legal status

Prescription only

Routes Oral, Intravenous

Verapamil (brand names: Isoptin, Verelan, Calan, Bosoptin) is an L-type calcium channel blocker. It has been used in the treatment of hypertension, angina pectoris, cardiac arrhythmia, and most recently, headaches.[1] Verapamil has also been used as a vasodilator during cryopreservation of blood vessels. It is a class 4 antiarrhythmic, more effective than digoxin in controlling ventricular rate, and was approved by the FDA in 1981. Interestingly, one of its purified isomers may not cause constipation (a well-known adverse effect of racemic verapamil).

Contents

Verapamil's mechanism in all cases is to block voltage-dependent Calcium channels.

In cardiac pharmacology, Calcium channel blockers are considered class IV antiarrhythmic agents. Since Calcium channels are especially concentrated in the sinoatrial and atrio-ventricular nodes, these agents can be used to decrease impulse conduction through the AV node, thus protecting the ventricles from atrial tachyarrhythmias.

Calcium channels are also present in the smooth muscle that lines blood vessels. By relaxing the tone of this smooth muscle, calcium-channel blockers dilate the blood vessels. This has led to their use in treating hypertension and angina pectoris.

The pain of angina is caused by a deficit in oxygen supply to the heart. Calcium channel blockers like Verapamil will dilate blood vessels, which increases the supply of blood and oxygen to the heart. This controls chest pain, but only when used regularly. It does not stop chest pain once it starts. A more powerful vasodilator such as nitroglycerin may be needed to control pain once it starts.

Given orally, 90–100% of Verapamil is absorbed, but due to high first-pass metabolism, bioavailability is much lower (10–35%). It is 90% bound to plasma proteins and has a volume of distribution of 3–5 L/kg-1. It is metabolized in the liver to at least 12 inactive metabolites (though one metabolite, norverapamil, retains 20% of the vasodilating activity of the parent drug). As its metabolites, 70% is excreted in the urine and 16% in feces; 3–4% is excreted unchanged in urine. This is a non-linear dependence between plasma concentration and dosage. Onset of action is 1-2 hours after oral dosage. Half-life is 5-12 hours (with chronic dosages). It is not cleared by hemodialysis.

Verapamil has an anti-manic effect but is rarely used for mania. It has on occasion been used used to control mania in pregnant patients, especially in the first 3 months. It does not appear to be significantly teratogenic. For this reason, when one wants to avoid taking valproic acid (which is high in teratogenicity) or lithium (which has a small but significant incidence of causing cardiac malformation), Verapamil is usable as an alternative, albeit presumably a less effective one.

Some possible side effects of the drug are headaches, facial flushing, dizziness, swelling, increased urination, and constipation.

Verapamil is also used in cell biology as an inhibitor of drug efflux pump proteins such as P-glycoprotein.[2] This is useful as many tumor cell lines overexpress drug efflux pumps, limiting the effectiveness of cytotoxic drugs or fluorescent tags. It's also used in fluorescent cell sorting for DNA content, as it blocks efflux of a variety of DNA-binding fluorochromes such as Hoechst 33342.

  1. ^ Management of Cluster Headaches, (Beck et al. 2005) American Family Physician Vol 71, No.4 Full Free Text: http://www.aafp.org/afp/20050215/717.html
  2. ^ Bellamy WT. P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 1996; 36:161-83. PMID 8725386

Advanced Search
Included Web Search Engines


Safe Search

close

Top Matching Results

Occasionally Search.com will highlight specialized results that are based on the context of your query. Examples of specialized results include specific links to news, images, or video.

Top Matching Results may highlight information from other Search.com pages, content from the CNET Network of sites, or third party content. The listings are based purely on relevance. Search.com does not receive payment for listings in this section but our partners that provide this data may get paid for listing these products.

Sponsored Links

This section contains paid listings which have been purchased by companies that want to have their sites appear for specific search terms and related content. These listings are administered, sorted and maintained by a third party and are not endorsed by Search.com.

Search Results

Search.com sends your search query to several search engines at one time and integrates the results into one list which has been sorted by relevance using Search.com's proprietary algorithm. You can customize the list of search engines included in your metasearch from the preferences.

The search engines that are used in your metasearch may allow companies to pay to have their Web sites included within the results. To view the Paid Inclusion policy for a specific search engine, please visit their Web site. Search.com does not accept payment or share revenue with any search engine partner for listings in this section.